{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:14:48Z","timestamp":1794244488446,"version":"4.9.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2021.633854","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T07:11:07Z","timestamp":1625728267000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Administration of Riluzole Oral Suspension During the Different Stages of Amyotrophic Lateral Sclerosis"],"prefix":"10.3389","volume":"12","author":[{"given":"M\u00f3nica","family":"Povedano Panades","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Couratier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Sidle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Sorar\u00f9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Tsivgoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert C.","family":"Ludolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1056\/NEJM200105313442207","article-title":"Amyotrophic lateral sclerosis","volume":"344","author":"Rowland","year":"2001","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/925101","article-title":"Amyotrophic lateral sclerosis: a focus on disease progression","volume":"2014","author":"Calvo","year":"2014","journal-title":"BioMed Res Int."},{"key":"B3","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/ane.12136","article-title":"Dysphagia in amyotrophic lateral sclerosis: prevalence and clinical findings","volume":"128","author":"Ruoppolo","year":"2013","journal-title":"Acta Neurol Scand."},{"key":"B4","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s40267-016-0312-7","article-title":"Riluzole oral suspension in amyotrophic lateral sclerosis: a guide to its use","volume":"32","author":"Keating","year":"2016","journal-title":"Drugs Ther Perspect."},{"key":"B5","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3389\/fneur.2017.00094","article-title":"Dysphagia in amyotrophic lateral sclerosis: impact on patient behavior, diet adaptation, and riluzole management","volume":"8","author":"Onesti","year":"2017","journal-title":"Front Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/j.1468-1331.2011.03501.x","article-title":"EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS) \u2013 revised report of an EFNS task force","volume":"19","year":"2012","journal-title":"Eur J Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"550","DOI":"10.3109\/17482968.2012.684215","article-title":"What is the relevance of percutaneous endoscopic gastrostomy on the survival of patients with amyotrophic lateral sclerosis?","volume":"13","author":"Pena","year":"2012","journal-title":"Amyotroph Lateral Scler."},{"key":"B8","unstructured":"Rilutek \u2013 Summary of Product Characteristics"},{"key":"B9","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S1474-4422(07)70244-2","article-title":"Clinical care of patients with amyotrophic lateral sclerosis","volume":"6","author":"Radunovi\u0107","year":"2007","journal-title":"Lancet Neurol."},{"key":"B10","unstructured":"Guideline on Clinical Investigation of Medicinal Products for the Treatment of Amyotrophic Lateral Sclerosis (ALS). EMA\/531686\/2015"},{"key":"B11","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJM199403033300901","article-title":"A controlled trial of riluzole in amyotrophic lateral sclerosis","volume":"330","author":"Bensimon","year":"1994","journal-title":"N Engl J Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/S0140-6736(96)91680-3","article-title":"Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis\/Riluzole Study Group II","volume":"347","author":"Lacomblez","year":"1996","journal-title":"Lancet"},{"key":"B13","first-page":"851","article-title":"Efficacy and safety of riluzole in patients with amyotrophic lateral sclerosis: double-blind placebo-controlled study in Japan","volume":"182","author":"Yanagisawa","year":"1997","journal-title":"Igakuno Ayumi."},{"key":"B14","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s004150200071","article-title":"A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis","volume":"249","author":"Bensimon","year":"2002","journal-title":"J Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"CD001447","DOI":"10.1002\/14651858.CD001447.pub3","article-title":"Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND)","volume":"2012","author":"Miller","year":"2012","journal-title":"Cochrane Database Syst Rev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"VI19","DOI":"10.1007\/PL00007784","article-title":"What has changed with riluzole?","volume":"247","author":"Meininger","year":"2000","journal-title":"J Neurol."},{"key":"B17","first-page":"60","article-title":"Survival in non-riluzole treated amyotrophic lateral sclerosis (ALS) - Motor neuron disease (MND) patients with disease onset before and since 1996 is identical: a clinic-based epidemiological study","volume":"2","author":"Brooks","year":"2001","journal-title":"ALS Mot Neuron Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/146608202317576499","article-title":"Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis","volume":"3","author":"Turner","year":"2002","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord."},{"key":"B19","first-page":"43","article-title":"Riluzole and prognosis in amyotrophic lateral sclerosis: findings of the Irish amyotrophic lateral sclerosis register over a five year study period 1995\u20132000","volume":"2","author":"Traynor","year":"2001","journal-title":"ALS."},{"key":"B20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/14660820500396984","article-title":"Audit of outcomes in motor neuron disease (MND) patients treated with riluzole","volume":"7","author":"Mitchell","year":"2006","journal-title":"Amyotroph Lateral Scler."},{"key":"B21","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/j.1468-1331.2006.01575.x","article-title":"Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy","volume":"14","author":"Zoccolella","year":"2007","journal-title":"Eur J Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2188\/jea.JE20120119","article-title":"Riluzole and prognostic factors in amyotrophic lateral sclerosis long-term and short-term survival: a population-based study of 1149 cases in Taiwan","volume":"23","author":"Lee","year":"2013","journal-title":"J Epidemiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3109\/21678421.2013.763281","article-title":"The impact of clinical factors, riluzole and therapeutic interventions on ALS survival: a population based study in Modena, Italy","volume":"14","author":"Georgoulopoulou","year":"2013","journal-title":"Amyotroph Lateral Scler Front Degener."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1136\/jnnp-2015-312908","article-title":"A clinical tool for predicting survival in ALS","volume":"87","author":"Knibb","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B25","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3389\/fnagi.2016.00246","article-title":"Long-term use of riluzole could improve the prognosis of sporadic amyotrophic lateral sclerosis patients: a real-world cohort study in China","volume":"8","author":"Chen","year":"2016","journal-title":"Front Aging Neurosci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2147\/DNND.S135748","article-title":"Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis","volume":"7","author":"Hinchcliffe","year":"2017","journal-title":"Degener Neurol Neuromuscul Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s00415-018-8778-y","article-title":"Riluzole and other prognostic factors in ALS: a population-based registry study in Italy","volume":"265","author":"Mandrioli","year":"2018","journal-title":"J Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S1474-4422(18)30054-1","article-title":"Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study","volume":"17","author":"Fang","year":"2018","journal-title":"Lancet Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2147\/DDDT.S123776","article-title":"Riluzole 5 mg\/ml oral suspension: for optimized drug delivery in amyotrophic lateral sclerosis","volume":"11","author":"Dyer","year":"2016","journal-title":"Drug Des Devel Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"229","DOI":"10.12968\/nrec.2006.8.5.20936","article-title":"Managing medicine for residents with swallowing problems","volume":"8","author":"Griffith","year":"2006","journal-title":"Nurs Resid Care."},{"key":"B31","first-page":"373","article-title":"Consensus guideline on the medication management of adults with swallowing difficulties.","volume-title":"Guidelines - Summarising Clinical Guidelines for Primary Care","author":"Wright","year":"2006"},{"key":"B32","unstructured":"Legal Consequences of Tablet Crushing"},{"key":"B33","unstructured":"Administering Drugs via Enteral Feeding Tubes. A guide for General Practitioners and Community Pharmacists"},{"key":"B34","first-page":"p. 752","volume-title":"Handbook of Drug Administration via Enteral Feeding Tubes","author":"White","year":"2015"},{"key":"B35","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1080\/21678421.2016.1232064\/004","article-title":"Bioequivalence study of Teglutik, an innovative oral suspension of riluzole, pharmacokinetic analysis in healthy volunteers. Theme 9","volume":"17","author":"Bettica","year":"2016","journal-title":"Ther Strateg Amyotroph Lateral Scler Front Degener."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejps.2018.09.004","article-title":"Rational design and development of a stable liquid formulation of riluzole and its pharmacokinetic evaluation after oral and IV administrations in rats","volume":"125","author":"Sarkar","year":"2018","journal-title":"Eur J Pharm Sci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/001857870403900308","article-title":"A guide to drug therapy in patients with enteral feeding tubes: dosage form selection and administration methods","volume":"39","author":"Beckwith","year":"2004","journal-title":"Hosp Pharm."},{"key":"B38","unstructured":"Teglutik \u2013 Summary of Product Characteristics"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1016\/j.clinthera.2019.09.016","article-title":"Riluzole oral suspension: bioavailability following percutaneous gastrostomy tube-modeled administration versus direct oral administration","volume":"41","author":"Brooks","year":"2019","journal-title":"Clin Ther."},{"key":"B40","unstructured":"Tiglutik \u2013 Highlights of Prescribing Information"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.633854\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T07:11:19Z","timestamp":1625728279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.633854\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,8]]},"references-count":40,"alternative-id":["10.3389\/fneur.2021.633854"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.633854","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,8]]},"article-number":"633854"}}